A ballyhooed deal has blown apart that
would have hooked up – for the first time – Big Pharma and the $3
billion California stem cell agency.

“We have recently been informed that
GSK was not able to obtain the final approval required due to
business reasons in the context of GSK's overall research and
development portfolio and investment needs and not as a result of any
scientific or technical assessment of ViaCyte's program.”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/p-E0ivzGfr0/collapse-of-big-pharma-deal-involving.html

Years ago, I worked with an editor who
used to advise his lagging scribes to put their noses in their
typewriters and peck.

CIRM staffers blogging the World Stem Cell Summit covered UC Davis researcher Paul Knoepfler discussing patient advocacy and its role in funding stem cell research.

The CIRM writers are doing double-duty
in at least one case. Geoff Lomax, the agency's senior officer for
its standards group, is additionally speaking on a panel at the session. A
handful of other CIRM officials are also appearing at the conference,
which ends tomorrow.

• “Claims of miracle cures for
  diseases
• “Single treatments or cells that
  can treat any type of disease
• “Lack of objective information,
  evidence (such as published medical reports) that a treatment is
  effective
• “Treatment by a doctor who is
  not trained or certified to treat the specific disease
• “No system exists to collect
  information and follow up with patients”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/usBXfuFwqy4/extra-extra-cirm-staffers-blog-world.html

Directors of the California stem cell
agency are expected to give away $80 million next week to 20
fortunate researchers in addition to exploring a “commercialization
and industry engagement plan.”

“This award will fund promising
physician scientists in the critical early stages of their careers as
independent investigators and faculty members establishing their own
laboratories and programs.” 

• More money – no amount yet specified
  – for Viacyte, Inc, of San Diego, which has received more than $36
  million from CIRM.
• An update of the agency's response to
  the only performance audit conducted at the agency. The audit
  identified 27 areas where improvement is needed, but the governing
  board has not discussed the results publicly since they were
  disclosed last May.
• Approval of the concept plan for
  another round of basic biology grants and adoption of conflict of
  interest code changes.

Interested parties will be able to take part at the meeting location in Los Angeles and teleconference locations in La Jolla, Oakland and UCSF. If you are interested in
the teleconference locations, you will need to contact the agency for more specific directions than are provided on the agenda.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/RU_xC86oAyw/80-million-in-grants-money-for-viacyte.html

Directors of the $3 billion California
stem cell agency are still mulling details of changes in their
free-wheeling and sometimes emotional appeals process for grant applications
that are rejected by the agency's reviewers.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/Hkq7zcXyMsQ/update-on-move-to-curb-researcher.html

An all natural skincare serum based on stemcells science
Independent clinical trials show DRAMATIC results - 25% fewer wrinkles,30% more moisture and 10% more elasticity...in just 28 days! Our breakthrough serum revitalizes the skin at the cellular level, to restore and maintain the skin #39;s youthful vibrance. DermaStem is a mocha-hued fusion of natural oils that blends invisibly into the skin. This all-natural serum contains a velvety emulsion of the world #39;s most restorative ingredients. This revolutionary product works to reduce the signs of premature aging by supporting the work of skin stem cells, the natural renewal system of the skin. For order online or more information,please contact us at http://www.myonline.stemtechbiz.com or email to fusioncreations@gmail.com.From:Tony Lim Careen SeeViews:1 0ratingsTime:06:48More inHowto Style

See the article here:
An all natural skincare serum based on stemcells science - Video

With millions of people in aggregate suffering from debilitating disease, reduced mobility, or relentless pain associated with various conditions, stem cell medicine is available now through WISE Surgical Solutions LLC by direct flight from some major cities to our Joint Commission International Accredited Johns Hopkins affiliated Punta Pacifica Hospital in Panama.

New York (PRWEB) December 06, 2012

Cathy Nenninger, Chief Executive Officer of WISE Surgical Solutions LLC, shared why this offering is important. When I ran wound centers up and down the east coast, I used to get calls from patients and family members desperate for treatments to help alleviate severe symptoms of ailments such as these. It was heartbreaking that we were not able to provide any type of help or hope to these patients. Granted, while the response and success of stem cell treatment in patients varies greatly and by disease, patients who are in extreme discomfort or experiencing reduced function or quality of life deserve to know that they have options available to them.

A significant element of PROJECT HOPE, continues Ms. Nenninger, is the opportunity for community funding of the treatment. Often, families and communities want to help someone by making donations that will collectively fund a surgery or procedure which in itself can add another chore to the already stressed world of a Care Captain (person seeking help for another); Our goal is to make the process easy. For more information on Project Hope, call (631) 942-6040 or for a quote for service, fill out a medical history form available at http://www.WISESurgicalSolutions.com.

WISE Surgical Solutions LLC is based out of New York and caters to companies and patients seeking quality healthcare at an affordable price inclusive of travel. Offerings include medical, dental and surgical procedures of most types, in-vitro fertilization (IVF) and stem cell medicine. Community & group funding as well as financing options are available for patients. Media relations inquiries can be directed to (631) 909-8538 or emailed to surgsolutions(at)optimum(dot)net.

Cathy M. Nenninger, MBA Wise Surgical Solutions LLC (631) 942-6040 Email Information

Here is the original post:
WISE Surgical Solutions LLC Announces Project Hope: Helping People with Debilitating Conditions Including Arthritis ...

Kell - ASD - 3 day after Stem Cell Treatment Part 2
For more information about ASD and Stem Cell Therapy, please visit worldstemcells.com © 2012 World Stem Cells LLCFrom:WorldStem CellsViews:2 2ratingsTime:17:14More inScience Technology

Originally posted here:
Kell - ASD - 3 day after Stem Cell Treatment Part 2 - Video

Making Stem Cell Thearpy Safer - Mayo Clinic
Mayo Clinic researchers have found a way to detect and eliminate potentially troublemaking stem cells to make stem cell therapy safer. Induced Pluripotent Stem cells, also known as iPS cells, are bioengineered from adult tissues to have properties of embryonic stem cells, which have the unlimited capacity to differentiate and grow into any desired types of cells, such as skin, brain, lung and heart cells. Study Author, Dr. Timothy Nelson provides and overview.From:mayoclinicViews:45 0ratingsTime:02:04More inScience Technology

See the rest here:
Making Stem Cell Thearpy Safer - Mayo Clinic - Video

GULF SHORES, Ala., Dec. 4, 2012 /PRNewswire/ --More than 75 percent of amyotrophic lateral sclerosis (ALS) patients who received neural reprogrammed stem cell therapy have shown a positive response to the procedure. The groundbreaking technique was introduced to the United States this year by Precision StemCell (http://www.precisionstemcell.com), an outpatient imaging and image-guided treatment facility located in Gulf Shores, Ala.

The procedure is performed by Dr. Jason R. Williams, a board-certified radiologist with extensive training in image-guided procedures. Under his care, 14 out of 18 patients diagnosed with ALS, also known as Lou Gehrig's disease, have shown signs of recovery.

"The improvements are mild, with patients reporting improved movement, breathing and speech, but we still have a long way to go," Dr. Williams stated. "Only time will tell how this therapy will affect the patients' long-term prognosis."

In Precision StemCell's neural reprogrammed stem cell therapy, fat-derived stem cells are injected into the spine of the patient. Dr. Williams uses a drug called selegeline, which has been shown to be a pre-inducer of adipose-derived stem cells into neural-like cells. Dr. Williams contends that the therapy is probably one of the largest advances seen in ALS therapy. "Before we started this therapy, I would have been happy just to see the progression of the disease halted, but to see some actual improvement, that was just shocking," he said

The first patient treated with the technique was Frank Orgel who continues to see improvement since his first treatment seven months ago. Eight years ago, Orgel's quality of life had declined to the point that he could not move his left arm or leg, walk or even stand on his own. The therapy has allowed Orgel to stand without assistance, and he continues to work with a physical therapist to regain the ability to walk. Another patient, Dexter Johnson, previously walked with a cane. After the treatment, Johnson has been able to walk without his cane for the majority of the time and he has been able to walk at a much faster pace.

The Precision StemCell center focuses on advanced imaging techniques, which include a 3T Open MRI, a low-dose 64-Slice CT Scanner, ultrasound and fluoroscopy, also known as real-time x-ray. The center is headed by Dr. Williams, who specializes in image-guided procedures, had already been performing magnetic resonance imaging (MRI), computed tomography (CT), ultrasound and fluoroscopy-guided stem cell injections for joint and orthopedic conditions.

In addition to their current work on advanced stem cell harvesting and processing with image-guided stem cell injections, Precision StemCell staff are planning to conduct further research so as to develop even more advanced techniques such as adding gene therapy to the current neural reprogramming platform. "Our therapy techniques not only hold promise for ALS patients, but also for people with other neural-related conditions such as Parkinson's and spinal cord injuries," said Dr. Williams. "There are several candidate genes that we plan to add to the adipose-derived stem cells and study in the mouse model. Though we are happy with our initial progress, our goal is to develop an effective cure."

About Precision StemCell

Located in Gulf Shores, Alabama, Precision StemCell conducts stem cell procedures using advanced imaging techniques, which include an Open 3T MRI, a low-dose 64-Slice CT scanner, ultrasound, and real time x-ray (fluoroscopy). Headed by Jason Williams, MD, a board-certified radiologist with extensive training in image-guided procedures, the facility performs advanced stem cell harvesting and processing with image-guided stem cell injections.

Contact:

View original post here:
Precision StemCell's Neural Reprogrammed Stem Cell Therapy Yields Better-Than-Expected Results for ALS Patients

.Rejuvenare Stem Cell Therapy 888-988-5456
Rejuvenare Autologous Adult Stem Cell Therapy welcome video asks and answers questions on whether someone is a candidate for stem cell therapy. More can be found at http://www.rejuvenare.comFrom:rejuvenareViews:2 0ratingsTime:01:01More inPeople Blogs

See more here:
.Rejuvenare Stem Cell Therapy 888-988-5456 - Video

NEW YORK, Dec. 3, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), an emerging leader in the fast growing cell therapy market, today announced that the Company and its subsidiary, Progenitor Cell Therapy ("PCT"), will present at multiple conferences in December.

World Stem Cell Summit

RedChip Small-Cap Equities Virtual Conference

Cell Therapy Manufacturing (Informa Life Sciences' 3rd Annual VIC Congress 2012)

American Society of Hematology Annual Meeting and Exposition ("ASH")

NeoStem's abstract on VSELTM Technology titled "A Lin-CD45-CD34+ Population of Extracellular Vesicles in Human Blood That Mimics Very Small Embryonic-Like Stem Cells (VSELs) by Flow Cytometry" has been selected for publication online in December in conjunction with the ASH Annual Meeting and Exposition, December 8-11, 2012. The abstract will be available at http://bloodjournal.hematologylibrary.org/site/misc/ASH_Meeting_Abstracts_Info.xhtml.

About NeoStem, Inc.

NeoStem, continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift occurring in medicine. We anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy industry. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, PCT, with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe that, with our expertise and research capabilities and collaborations, we will achieve our mission of becoming a premier cell therapy company.

Our contract development and manufacturing service business supports the development of proprietary cell therapy products. NeoStem's most clinically advanced therapeutic, AMR-001, is being developed at Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011. Amorcyte is developing a cell therapy for the treatment of cardiovascular disease and is enrolling patients in a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. Athelos Corporation ("Athelos"), which is 80%-owned by our subsidiary, PCT, is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. In addition, pre-clinical assets include our VSELTM Technology platform as well as our mesenchymal stem cell product candidate for regenerative medicine. Our service business and pipeline of proprietary cell therapy products work in concert to create a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a substantial intellectual property estate, we are well positioned to succeed.

For more information, please visit http://www.neostem.com.

Original post:
NeoStem to Present at Multiple Conferences in December

Introduction

Genetic disorders are becoming common nowadays due to stressful modern lifestyle. Latest technologies are the added values to create many genetic disorders. To overcome the disorders, Gene therapy is a blessing. In order to compensate abnormal genes and make a good gene, genetic material is introduced into cells. In this way, mutated gene will act as a normal gene. Let us see in detail.

Ways to insert the gene

There are indirect ways need to be followed to make a gene to function as if it is inserted directly does not function. Carrier also called as vector is used to deliver the gene. In the place of vectors, virus play the role as they are getting modified and hence people are not affected with new diseases when it is integrated into the chromosome of the human cell.

The vectors need to get injected to specific tissue in the body or outwardly patient’s cell is removed and exposed to the vector. In either of the ways need to be again returned to the patient. Successful treatment makes proper genes and genetic disorders get solved.

Gene therapy for treating cancer

Cancer is the dangerous disease and there are many ways to cure cancer including surgery, chemotherapy, and radiation. But cancerous cells in due course again spread and hence it is a deadly disease. Gene therapy is the best way discovered nowadays for treating cancer.
Let us see the basic fundamentals of cells. cells include packets of data in genes, created either from DNA or RNA. Sequence is there for DNA and if it is in the order, there will be no problem. But at the same time If there is disorder occurs in portion of the genes either turning or changing the position, cells lost their control and abnormal growth is seen which result in cancerous tumors. It can spread in mouth, breast, lung etc.,

Specialists in Gene therapy analyze the patient’s criticality first and follow the treatment procedures. One way is they replace missing or mutated genes into wholesome genes. Inserting totally new genes for fighting cancer, placing DNA into cancerous cells to undergo chemotherapy and radiation or injecting bad gene to destroy them etc., Mesothelioma type of cancers are not at all responded in formal therapies and hence one need to undergo gene therapy essentially. Need to have consultations with doctors to overcome their deadly disease.

Gene therapy importance

Doctors decide whether gene therapy is suitable by the following approaches. If genetic disorders are from mutations in one or more genes or whether a normal copy of the gene that is available in the patient is enough to fix the problems in the affected cells, then doctors determine that gene therapy will be more helpful rather than going for traditional methods.

Conclusion

Genetic engineering is a vast topic. Latest Science innovations in the field of genetic engineering yields for gene therapy. Doctors and scientists together working to find out whether gene therapy is the best suitable way for treating deadly diseases like cancer and others. Let us salute for the positive force of gene therapy.

Source:
http://www.biotechblog.org/entry/biotechnology-gene-therapy/

Today's THV

Gene Patents Draw High Court Review in Biotechnology Test Businessweek The U.S. Supreme Court agreed to consider whether human genes can be patented, taking up an issue that has split the medical community and will shape the future of personalized health care and the biotechnology industry. The justices yesterday said ... US Supreme Court to Review Patents on Human GenesWall Street Journal Supremes to Decide Others Can Own Your GenesNational Review Online (blog) US top court to rule if companies can patent genesAFP Philadelphia Inquirer all 313 news articles »

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNHkE9GDvUDADfqatAhvvW4OD3C8XA&url=http://www.businessweek.com/news/2012-11-30/gene-patents-draw-high-court-review-in-biotechnology-test

Genetic Engineering News

DuBiotech: The Silicon Valley of Biotechnology Genetic Engineering News Ahmed Taha from DuBiotech, the Dubai Biotechnology & Research Park, has two questions for GEN readers: “Do you have a biotech idea that you'd like to develop rapidly, conveniently, and inexpensively?” Or alternatively, “Do you have an existing biotech ... and more »

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNEk4rtzm46lE_25U_ZbxuqBzc6dnA&url=http://www.genengnews.com/insight-and-intelligence/dubiotech-the-silicon-valley-of-biotechnology/77899729/

The panelists emphasized that more accurate information should be provided to the public regarding stem cell treatments.

1.  50 shades of grey. Let's admit that this issue is not black-and-white but, as is almost always, involves a broad spectrum of grey in the middle.  


In addition to helping patients distinguish between compliant and non-compliant treatments (and providers) there are a lot of ways to help patients distinguish between non-compliant cell therapy  treatments (and providers) which are more or less risky.  

In between - in my opinion - are clinics like Stem Cell Institute and StemCellMD.

For some, helping patients distinguish between the better and worst non-compliant clinics might involve a fair amount of nose-pinching but this is the equivalent of the methadone clinic for heroine addicts.  By supporting the better of two evils we are not endorsing it as 'good', we are simply recognizing it is better.

This is a recognition that we cannot just abandon people because they made (or are going to make) decisions with which we ultimately disapprove.   It is a recognition that sometimes the most righteous thing to do is not only to help people do what we would ideally want them to do but to help them do the best they can in their circumstances and on their terms - even terms with which we may ultimately disagree.

6.  Let's grow a pair and call a spade a spade.  If a non-compliant clinic is providing treatments that we believe represent a high-risk to patient safety and the industry's credibility, let's have the b*lls to call them on it.  They can't sue everyone.  

http://www.celltherapyblog.com hosted by http://www.celltherapygroup.com

Source:
http://feedproxy.google.com/~r/CellTherapyBlog/~3/2b8Ffw4b1pU/six-steps-to-fighting-non-compliant.html

Scientists and engineers dream about big advances that could change the world, and then they try to create them. On the following pages, Scientific American reveals 10 innovations that could be game changers: an artificial alternative to DNA, oil that cleans water, pacemakers powered by our blood, and more. These are not pie-in-the-sky notions but practical breakthroughs that have been proved or prototyped and are poised to scale up greatly. Each has the potential to make what may now seem impossible possible. -- The Editors

[More]

Source:
http://rss.sciam.com/click.phdo?i=b2ba3706ed26d9143fea77a07b425555

A couple of members of the governing
board of the $3 billion California stem cell agency were honored for
their work this month.

Jeff Sheehy UCSF Photo

“Jeff once told me
that when he joined CIRM’s board eight years ago, he didn’t see a
role for stem cells in an HIV/AIDS treatment. Now, CIRM has committed
$40 million toward HIV/AIDS projects and two teams of researchers
from City
of Hope and UCLA are
working toward clinical trials.”

Bert Lubin Childrens Hospital Photo

“He recruited a new senior management
team, chopped away at the pediatric hospital’s operating deficit
and worked to heal relationships with the local community and
governmental and political leaders that were deeply frayed...”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/9b9s3mW2ebM/stem-cell-board-members-lubin-and.html

Longtime ALS patient advocate Diane
Winokur of San Francisco, who has lost two sons to the disease, has
been appointed to the governing board of the $3 billion California
stem cell agency.

Diane Winokur Photo -- Legal Momentum

"Her
contributions have been invaluable and she will be a tremendous asset
in moving the ALS research field forward through CIRM
funding."

“Her knowledge, expertise and
leadership will be a tremendous addition to the ICOC (the stem cell
agency governing board) and help guide us in our work.”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/dITcyP7WJbs/diane-winokur-veteran-als-patient.html

As of this week, 14 persons have been
recommended for the Knoepfler “Stem Cell Person of the Year”
Award.

“It’s something that I’m hoping I
can do every year. It would also be a reward for risk taking,
creativity and be breaking with tradition and be something new in
that regard.” 

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/cLYLc5HQUSY/knoepfler-award-update-more-than-bakers.html

Study moves scientists one step closer to creating youthful heart patches from old cells

TORONTO, ON A new method of growing cardiac tissue is teaching old stem cells new tricks. The discovery, which transforms aged stem cells into cells that function like much younger ones, may one day enable scientists to grow cardiac patches for damaged or diseased hearts from a patients own stem cellsno matter what age the patientwhile avoiding the threat of rejection.

Stem cell therapies involving donated bone marrow stem cells run the risk of patient rejection in a portion of the population, argues Milica Radisic, Canada Research Chair in Functional Cardiovascular Tissue Engineering at the Institute of Biomaterials and Biomedical Engineering (IBBME) and Associate Professor in the Department of Chemical Engineering and Applied Chemistry at the University of Toronto.

One method of avoiding the risk of rejection has been to use cells derived from a patients own body. But until now, clinical trials of this kind of therapy using elderly patients own cells have not been a viable option, since aged cells tend not to function as well as cells from young patients.

Its a problem that Radisic and her co-researcher, Dr. Ren-Ke Li, think they might have an answer for: by creating the conditions for a fountain of youth reaction within a tissue culture.

Li holds the Canada Research Chair in Cardiac Regeneration and is a Professor in the Division of Cardiovascular Surgery, cross-appointed to IBBME. He is also a Senior Scientist at the Toronto General Research Institute.

Radisic and Li first create a micro-environment that allows heart tissue to grow, with stem cells donated from elderly patients at the Toronto General Hospital.

The cell cultures are then infused with a combination of growth factorscommon factors that cause blood vessel growth and cell proliferationpositioned in such a way within the porous scaffolding that the cells are able to be stimulated by these factors.

Dr. Li and his team then tracked the molecular changes in the tissue patch cells.

We saw certain aging factors turned off, states Li, citing the levels of two molecules in particular, p16 and RGN, which effectively turned back the clock in the cells, returning them to robust and healthy states.

See more here:
“Fountain of Youth” technique rejuvenates aging stem cells - Study moves scientists one step closer to creating ...